SOURCE: PR Newswire
FDA, NIH, and Industrial Stem Cell Leaders to Address Implications of
Stem Cell Research at Annual Conference in Princeton, NJ
NEW YORK, Oct. 13 /PRNewswire/ -- The FDA's regulatory oversight,
allocation of NIH support, and new approaches in stem cell research and
regenerative therapeutics will be among the many key topics presented by
industrial and academic leaders at a two-day conference held annually in
Princeton, NJ, announces Strategic Research Institute.
The meeting is the fourth in the series, and has gained industry-wide
recognition for its comprehensive inclusion of pharma, biotech, and
academia
in a single, two-day event.
Topics to be covered include: Therapeutic Potential of Neural Stem
Cells,
Pharmaceutical Approaches to Triggering Tissue Repair and Regeneration,
Human
Adult Bone-Derived Stem Cells for Pro-Regenerative Tissue Repair, Stem
Cells
in Cellular Assay Design for Screening, Immunosuppressive Effects of
Human
Mesenchymal Stem Cells, among many others.
Faculty includes: Aventis Pharmaceuticals, StemCells Inc., Stem Cell
Sciences, Eli Lilly, Novartis Institutes for Biomedical Research, Osiris
Therapeutics, Wisconsin Alumni Research Foundation/WiCell, and the
President's
Council on Bioethics.
An academic keynote entitled "The Future of Stem Cell Research in New
Jersey," will be presented by Dr. Wise Young, Professor II, Department of
Cell
Biology and Neuroscience, RutgersUniversity, and Director,
W.M.KeckCenterfor
Collaborative Neuroscience.
Agenda, updated information, and registration is available online at
http://www.srinstitute.com/cs309
For further information, including group discounts and speaking
opportunities, please contact Steve J. Kuperberg at
[log in to unmask]
or call (212) 967-0095 ext. 261.
SOURCE Strategic Research Institute
Web Site: http://www.srinstitute.com
http://www.srinstitute.com/cs309
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
